Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy
- 22 June 2024
- journal article
- review article
- Published by Springer Nature in Phenomics
- Vol. 4 (4) , 401-414
Abstract
Cancer immunotherapy has made great progress in effectively attacking or eliminating cancer. However, the challenges posed by the low reactivity of some solid tumors still remain. Macrophages, as a key component of the tumor microenvironment (TME), play an important role in determining the progression of solid tumors due to their plasticity and heterogeneity. Targeting and reprogramming macrophages in TME to desired phenotypes offers an innovative and promising approach for cancer immunotherapy. Meanwhile, the rapid development of in vivo molecular imaging techniques provides us with powerful tools to study macrophages. In this review, we summarize the current progress in macrophage reprogramming from conceptual roadmaps to therapeutic approaches, including monoclonal antibody drugs, small molecule drugs, gene therapy, and chimeric antigen receptor-engineered macrophages (CAR-M). More importantly, we highlight the significance of molecular imaging in observing and understanding the process of macrophage reprogramming during cancer immunotherapy. Finally, we introduce the therapeutic applications of imaging and reprogramming macrophages in three solid tumors. In the future, the integration of molecular imaging into the development of novel macrophage reprogramming strategies holds great promise for precise clinical cancer immunotherapy.Keywords
Funding Information
- the State Key Program of National Natural Science Foundation of China (32330048)
- The National Natural Science Foundation of China (82371857)
- Hainan University Scientific Research Foundation (KYQD(ZR)20078)
This publication has 97 references indexed in Scilit:
- MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinomaCancer Cell, 2023
- Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapyScience China Life Sciences, 2023
- Tumor‐associated macrophages in liver cancer: From mechanisms to therapyCancer Communications, 2022
- Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancerCell, 2022
- Anti‐Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarizationMolecular Oncology, 2021
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancerCancer Cell, 2021
- Nucleic acid delivery for therapeutic applicationsAdvanced Drug Delivery Reviews, 2021
- Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer TherapyAdvanced Materials, 2021
- Advancing to the era of cancer immunotherapyCancer Communications, 2021
- Metabolic reprogramming and epigenetic modifications on the path to cancerProtein & Cell, 2021